Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr Blood Cancer 2013 Jun;60(6):994-1000
Date
12/21/2012Pubmed ID
23255438Pubmed Central ID
PMC4127041DOI
10.1002/pbc.24419Scopus ID
2-s2.0-84876430490 (requires institutional sign-in at Scopus site) 171 CitationsAbstract
Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.
Author List
Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, Gratias EJ, Dix DB, Ehrlich PF, Khanna G, Malogolowkin MH, Anderson JR, Naranjo A, Perlman EJ, COG Renal Tumors CommitteeMESH terms used to index this publication - Major topics in bold
Chemotherapy, AdjuvantChild
Clinical Trials as Topic
Humans
Kidney Neoplasms
Nephrectomy
Research
